ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Stroke"

  • Abstract Number: 2631 • ACR Convergence 2024

    Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study

    Pierre Loiseau1, Aurélie Mailhac2, Pierre Duhaut1, Henrik Toft Sørensen2 and Reimar W Thomsen2, 1Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, 2Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
  • Abstract Number: 0744 • ACR Convergence 2024

    Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry

    Adrián Martín-Gutiérrez1, Juan Molina-Collada2, Marta Domínguez-Álvaro3, Rafael Benito Melero-Gonzalez4, Elisa Fernández-Fernández:5, Maite Silva-Diaz6, Jesús Alejandro Valero7, Ismael Gonzalez8, Julio Sánchez-Martín9, Javier Narvaez-García10, Itziar Calvo11, Vicente Aldasoro12, lydia Abasolo Alcazar13, ALBERTO MARIANO RUIZ ROMAN14, Javier Loricera15, Santos Castañeda16, Clara Molina Almela17, María Alcalde Villar:18, Antonio Juan-Mas19 and Ricardo Blanco-Alonso20, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4CHU Ourense, O Carballino, Spain, 5La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 6Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 7Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, 8Complejo Asistencial Universitario de Leon, León, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital Universitario de Bellvitge, Barcelona, Spain, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Universitario de Navarra, Pamplona, Spain, 13IdISSC. HCSC, Madrid, Spain, 14Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, 15Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 16Hospital Universitario de la Princesa, Madrid, Spain, 17Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 18Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 19Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 20Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
  • Abstract Number: 0761 • ACR Convergence 2024

    An Observational Study of Lifetime Prevalence of Thromboembolism Among Patients with Giant Cell Arteritis

    Ioannis Koulas1, Nikolaos Tsaftaridis2, Ivana Ilic3, Jack Jnani4, Alex Spyropoulos1 and Lara El Khoury5, 1Feinstein Institutes for Medical Research/Northwell Health, Manhasset, 2Feinstein Institutes for Medical Research/Northwell Health, Manhasset, NY, 3Northwell, Brooklyn, NY, 4Department of Medicine/Northwell Health, Manhasset, 5Division of Rheumatology/Northwell Health, Great Neck, NY

    Background/Purpose: Studies indicating a higher incidence rate of stroke and venous thromboembolism (VTE) among patients with giant cell arteritis (GCA) hint at a possible association between…
  • Abstract Number: 1188 • ACR Convergence 2024

    High Risk of Stroke in Men with Joint Prosthesis Due to Osteoarthritis: The Prospective STRAMBO Study

    MAXIME AUROUX1, PAWEL SZULC2 and ROLAND CHAPURLAT1, 1Hospices Civls de Lyon, LYON, Rhone-Alpes, France, 2INSERM U1033, LYON, Rhone-Alpes, France

    Background/Purpose: Osteoarthritis (OA) and cardiovascular disease share risk factors. The impact of OA on cardiovascular and especially cerebrovascular outcomes is still debated. Our aim was to…
  • Abstract Number: 1279 • ACR Convergence 2024

    Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes

    Ekemini Ogbu1, Jareen Meinzen-Derr2, Michael Wagner2, Rashmi Sahay2, Dhriti Sharma2, J Michael Taylor2, Sudhakar Vadivelu3, Mekibib Altaye2 and hermine brunner1, 1Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Cerebrovascular accidents (CVA) are one of the most devastating neurologic manifestations of childhood-onset systemic lupus erythematosus (cSLE).  The spectrum of CVA in cSLE (CVAcSLE)…
  • Abstract Number: 2009 • ACR Convergence 2024

    Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes

    Amara Sarwal1, Augustine Takyi1, Guo Wei1, McKenna Nevers1, Ravinder Singh1, Sydney Hartsell1, Robert Boucher1, Niharika Katkam1, Akhil Chakravartula1, Jincheng Shen1, Srinivasan Beddhu1 and Naomi Schlesinger2, 1University of Utah, VA Salt Lake City Health Care System, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…
  • Abstract Number: 0107 • ACR Convergence 2023

    Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020

    Sami Rabah, Lincoln Medical Center, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is recognized for its association with an elevated risk of ischemic strokes and other thromboembolic events. This study aims to compare…
  • Abstract Number: 0178 • ACR Convergence 2023

    Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus

    Saloni Patolia, Dulaney Wilson, Jim Oates and Diane L. Kamen, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Even among young women with systemic lupus erythematosus (SLE), accelerated atherosclerosis and coronary artery disease are common complications. Traditional risk scoring methods underestimate cardiovascular…
  • Abstract Number: 0552 • ACR Convergence 2023

    The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus

    YuFang Ding1, Can Huang2, Jiuliang zhao3, Qian Wang1, Xinping Tian3, Mengtao Li3 and xiaofeng Zeng1, 1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Peking Unoin Medical College Hospital, Beijing, China, 3Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases (23·3 events per 1000 patient-years). Antiphospholipid antibodies (aPLs), including anticardiolipin…
  • Abstract Number: 0744 • ACR Convergence 2023

    Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus

    May Choi1, Hongshu Guan2, Kazuki Yoshida3, Benjamin Kargere4, Jack Ellrodt5, Emma Stevens2, Tianrun Cai2, Brendan Everett2, Brittany Weber2 and Karen Costenbader6, 1University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital, Boston, MA, 3Takeda, Boston, MA, 4Williams College, Boston, MA, 5Williams College, Williamstown, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…
  • Abstract Number: 1150 • ACR Convergence 2023

    A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era

    Carmen Lasa1, Maria Enriqueta Peiró2, Juan Irure-Ventura2, Amparo Sánchez2, Adrian Martin-Gutierrez2, carmen secada2, monica renuncio garcia2, Marcos Lopez-Hoyos3 and Ricardo Blanco4, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cryofibrinogenemia (CF) is an under-recognized syndrome due to the lack of definitive criteria and the rarity of disease. CF may be primary (essential) or…
  • Abstract Number: 1241 • ACR Convergence 2023

    Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort

    Stephanie Fevrier1, Olivia Hendrikx1, Ashley Danguecan1, Asha Jeyanathan1, Lawrence Ng1, Ibrahim Mohamed2, Paris Moaf1, Sondos Ayyash1, Chelsea DeCoste3, Deborah Levy1, Linda Hiraki1 and Andrea Knight1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Brampton, ON, Canada, 3IWK Health Centre, Halifax, NS, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…
  • Abstract Number: 1442 • ACR Convergence 2023

    Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus

    Renata Baronaite Hansen1, Julia Simard2, Mikkel Faurschou1 and Søren Jacobsen3, 1Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 3Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…
  • Abstract Number: 2254 • ACR Convergence 2023

    The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2, Ruru Guo3 and Bharat Kumar4, 1University of Iowa Hospitals and Clinics, Coralville, IA, 2The Wright Center for Graduate Medical Education, Scranton, PA, 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
  • Abstract Number: 2384 • ACR Convergence 2023

    Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group

    Lisa Rosenberg1, Larabe Farrukh1, Simrin Kooner1, Moiz Ehtesham1, Sumbal Wajid1, Ruben Peredo-Wende2 and Shannon Murawski1, 1Albany Medical Center, Albany, NY, 2Stratton VA Medical Center, Albany, NY

    Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology